P.M. BRIEFING : Drug Firm Admits False Data
Attorneys for Bolar Pharmaceutical Co. Inc. told government regulators that the company appears to have used false documents to fight government action against one of its generic drugs, according to letters released today.
The leaders of a House investigations subcommittee, which released the letters, said it appears the company was involved in a criminal cover-up and called for Bolar to remove its generic drug Dyazide from the market.
Dyazide is a widely prescribed high blood pressure medication made by SmithKline Beecham. Two generic versions of the drug were approved by the Food and Drug Administration.
Vitarine Pharmaceuticals of Springfield Gardens, N.Y., took its version off the market last year after it admitted cheating on tests required to win FDA approval.
Bolar makes the only other generic Dyazide, and the drug is the company’s largest-selling product.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
